title: Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
abstract: The effects of zileuton, a new 5-lipoxygenase inhibitor, on leukotriene generation and clinical response in rheumatoid arthritis (RA) was studied in a 4-week randomized double blind placebo controlled study at 2 academic rheumatology centers. Zileuton decreased the mean (+/- SEM) ionophore induced synthesis of leukotriene B4 at Week 1 by 70% from 191.2 +/- 28.5 to 57.5 +/- 17.0 ng/ml. A parallel suppression of all major 5-lipoxygenase pathway products was observed. An improvement in clinical variables was observed in the zileuton and placebo treated population. No unique toxicity was identified in this study. Zileuton inhibited 5-lipoxygenase in RA with a suggestion of clinical response with limited toxicity.
authors.affiliation: Department of Rheumatology/Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
authors.forename: M E
authors.initials: ME
authors.lastname: Weinblatt
authors.forename: J M
authors.initials: JM
authors.lastname: Kremer
authors.forename: J S
authors.initials: JS
authors.lastname: Coblyn
authors.forename: S
authors.initials: S
authors.lastname: Helfgott
authors.forename: A L
authors.initials: AL
authors.lastname: Maier
authors.forename: G
authors.initials: G
authors.lastname: Petrillo
authors.forename: B
authors.initials: B
authors.lastname: Henson
authors.forename: P
authors.initials: P
authors.lastname: Rubin
authors.forename: R
authors.initials: R
authors.lastname: Sperling
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007975:Leukotriene B4 / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016859:Lipoxygenase Inhibitors; D007975:Leukotriene B4; C063449:zileuton; D006918:Hydroxyurea